Published in Blood Weekly, December 15th, 2005
BioTime's third quarter revenues for 2005 include $87,541 in funds as part of a $299,990 grant from the National Heart, Lung, and Blood Institute division of the National Institutes of Health (NIH) for use in the development of HetaCool.
The NIH grant was renewed in April 2005 following the submission of a satisfactory progress report on the project. BioTime did not recognize any grant revenue in the same period last year.
Royalty revenues from Hextend product sales in the United States and Canada...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.